Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI

Схожие документы

• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  по: Imamura, Fumio, et al.
  Опубликовано: (2020)
• The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
  по: Tamiya, Motohiro, et al.
  Опубликовано: (2021)
• Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
  по: Peng, MuYun, et al.
  Опубликовано: (2020)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  по: Kejing Tang, et al.
  Опубликовано: (2019-02-01)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  по: Tang, Kejing, et al.
  Опубликовано: (2018)